Abinav Baweja, MD
Medical Oncology · Pleasanton, CANPI 1770961575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 7.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,858 and has fallen 97.1% since, to $53 in 2025. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 109 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$184
- Johnson & Johnson$179
- Merck$159
- Bristol Myers Squibb$152
- Daiichi Sankyo Inc.$141
- E.r. Squibb & Sons, L.L.C.$127
- plus $2K from 29 others
What the payments were for
- Food & beverage$2,46797%
- Education$823%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 7 | $184 |
| Johnson & Johnson | 11 | $179 |
| Merck | 6 | $159 |
| Bristol Myers Squibb | 6 | $152 |
| Daiichi Sankyo Inc. | 7 | $141 |
| E.r. Squibb & Sons, L.L.C. | 8 | $127 |
| Exelixis Inc. | 2 | $127 |
| Sanofi | 4 | $122 |
| Pfizer | 6 | $116 |
| Amgen | 5 | $113 |
| Taiho Oncology, Inc. | 5 | $99 |
| Genentech USA, Inc. | 3 | $93 |
| AstraZeneca | 4 | $88 |
| Gilead(2 entities) | 4 | $84 |
| Sanofi-aventis U.S. LLC | 1 | $82 |
| Novartis | 3 | $78 |
| Alnylam Pharmaceuticals Inc. | 3 | $57 |
| Astellas Pharma US Inc | 2 | $50 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $48 |
| Bayer | 2 | $46 |
| EMD Serono, Inc. | 2 | $43 |
| Eisai Inc. | 2 | $36 |
| GSK | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Octapharma USA, Inc. | 1 | $27 |
| Tactile Systems Technology Inc | 1 | $26 |
| Immunogen, Inc. | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Foundation Medicine, Inc. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $22 |
| Incyte Corporation | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $18 |
How this compares
$2,549 in reported general payments places this provider in the 40th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $25,555 |
| XareltoRivaroxaban | 15 | $11,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $116 | $25,55516 claims |
| Johnson & JohnsonXarelto | $179 | $11,50715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 379 medical oncology providers in California.
Other medical oncology in Pleasanton
- Rishi SawhneyPleasanton$162K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.